Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline of presentation
- Definition of anaemia
- Agenda - prevalence of anaemia in CKD
- Renal anaemia
- Evolution of anaemia in CKD prior to EPO therapy
- Prevalence of anaemia in CKD Patients
- Agenda - causes of CKD anaemia
- Causes of CKD anaemia
- Erythropoiesis in CKD
- EPO levels in renal anaemia
- CKD patients prone to develop iron deficiency
- Agenda - how to treat anaemia in CKD
- 3 steps to management of CKD anaemia (1)
- Exclude another cause for anaemia
- 3 steps to management of CKD anaemia (2)
- Erythropoiesis
- Markers of iron status
- Monitoring iron status
- Iron supplementation
- Absorption of oral iron in HD patients
- IV iron preparations
- Elimination kinetics of different IV irons
- What do we know about IV iron?
- 3 steps to management of CKD anaemia (3)
- Development of recombinant human EPO
- Recombinant human EPO
- Benefits and harms of anaemia correction
- Hb correction with ESAs - the good old days
- Correction of anaemia - benefits
- Hb correction with ESAs - the bad days
- Hb correction with ESAs - clinical trials
- The TREAT study
- TREAT study – Hb response
- Safety concerns in the TREAT study
- Hb correction with ESAs - summary
- EPO has non-erythropoietic actions
- Anaemia guidelines (1)
- Anaemia guidelines (2)
- Future of CKD anaemia management
- Future of CKD anaemia treatment: HIF stabilisers
- Regulation of erythropoietin
- HIF stabilisers
- Erythropoietin concentration-time profiles
- HIF PHIs in development
- Roxadustat in CKD anaemia
- Conclusions
- Concluding remarks
Topics Covered
- Definition of anaemia
- Prevalence of anaemia in CKD (renal anaemia)
- Causes of CKD anaemia
- How to treat anaemia in CKD (3 steps of management, iron status and supplementation, ESA therapy)
- Benefits and harms associated with correction of anaemia
- Future of CKD anaemia management (HIF stabilisers)
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Macdougall, I. (2016, September 29). Anaemia in chronic kidney disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 24, 2024, from https://doi.org/10.69645/XCGN1199.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Iain Macdougall has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: The Kidney in Health and Disease
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Iain Macdougall.
I'm a Consultant Nephrologist and Professor
of Clinical Nephrology in the Renal Unit,
King's College Hospital in London.
I've been invited to talk to you
in this presentation
about Anemia in Chronic Kidney Disease,
a topic that I've had a long-standing
clinical and research interest
over the last two or three decades.
0:22
The topics I would like
to cover specifically
in relation to this presentation
are six-fold.
I would like to, first of all,
discuss the definition of anemia
in general population
and specifically
in chronic kidney disease.
I would like to look
at the prevalence of anemia
in this patient population.
I would like to discuss
the causes of the condition,
how to treat it, and specifically
what the benefits
and possible harms
associated with treating anemia might be,
and then just a brief word at the end
about the future of CKD anemia management.
1:00
So I will start
with the definition of anemia.
In the general population,
the things are quite well-defined
according to the World Health Organization
definition of anemia which was
first talked about in the 1960s
and is still quoted to today.
So in men, anemia is defined
by the World Health Organization
as hemoglobin concentration
of less than 13 gram per deciliter
or in modern parlance 130 grams per liter.
Women generally have lower hemoglobin,
and according
to the World Health Organization,
their anemia is defined as a hemoglobin
less than 12 grams per deciliter
or in modern parlance 120 gram per liter.
The reason for this discrepancy
is often thought to be the fact
that young women menstruate monthly
and that is definitely part
of the reason for this,
but also recognized that testosterone
plays a major part in red cell development.
And, of course, men have
higher levels of testosterone
than women, so that's one of major reasons
why men have higher hemoglobin
generally than women.
In the field of chronic kidney disease,
things are slightly different,
and the threshold hemoglobin
for chronic kidney disease,
both men and women is a hemoglobin
less than 11 gram per deciliter
or 110 gram per liter.
The reasons for this are largely related
to the thresholds for treatment
and also the fact
that this is a chronic anemia
and patients with this condition
with renal disease adapt
to having lower hemoglobin levels
and therefore it's accepted
that the definition of anemia
is lower than in the general population.